Literature DB >> 26394920

Evaluation of breviscapine on prevention of experimentally induced abdominal adhesions in rats.

Hui Zhang1, Yu Song1, Zhiyong Li2, Ting Zhang3, Li Zeng4.   

Abstract

BACKGROUND: Adhesion formation, which results from mechanical peritoneal damage, tissue ischemia, or the presence of foreign materials, is a complicated process. The formation of adhesions is associated with inflammatory response and extracellular matrix deposition in response to injury. Although the pathophysiology of adhesion formation is widely understood, an absolute solution to this problem does not exist yet. As a main component of Erigeron breviscapus, breviscapine has exhibited the ability of anti-inflammatory and antifibrosis on many diseases. The purpose of this study was to investigate the effect of breviscapine on the development of postoperative intra-abdominal adhesions in Wistar rats.
METHODS: Abdominal adhesions were induced by scraping the cecum in rats. Various dosages of breviscapine drugs were administered for 10 days after surgery. On the 11th day after surgery, the levels of interleukin (IL) 18, IL-6, tumor necrosis factor α in blood serum and transforming growth factor β1 (TGF-β1), connective tissue growth factor, tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1) in peritoneal fluid were determined by enzyme linked immunosorbent assay. The expression of Smad7 and TGF-β1 in rat cecum tissue was evaluated by Western blot analysis. Grades of intestinal adhesion were ranked by macroscopic observation.
RESULTS: The intraperitoneal administration of breviscapine is effective on the prevention of the formation of postoperative adhesions in rats. Breviscapine decreased the levels of IL-18, IL-6, and tumor necrosis factor-α in blood serum and TGF-β1, connective tissue growth factor, PAI-1 in peritoneal fluid. But the levels of tPA and the ratio of tPA and PAI-1 in peritoneal fluid were increased. In addition, breviscapine significantly inhibited the expression of TGF-β1 and increased the level of Smad7 in the rat cecum tissue.
CONCLUSIONS: These results suggested that intraperitoneal administration of breviscapine was effective in preventing intra-abdominal adhesion formation in rats. Breviscapine appears to have synergetic effects which could decrease fibrosis by inhibiting inflammation, upregulating peritoneal fibrinolytic activity and regulating the TGF and/or Smad signaling pathway. These data indicated a potential new therapeutic use of breviscapine on adhesion prevention.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abdominal adhesions; Breviscapine; Smad7; TGF-β(1)

Mesh:

Substances:

Year:  2015        PMID: 26394920     DOI: 10.1016/j.amjsurg.2015.05.037

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  10 in total

1.  Postoperative peritoneal adhesion: an update on physiopathology and novel traditional herbal and modern medical therapeutics.

Authors:  Setareh Soltany
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-09-26       Impact factor: 3.000

2.  Prevention of post-surgical adhesion bands by local administration of frankincense n-hexane extract.

Authors:  Fatemeh Jamshidi-Adegani; Saeid Vakilian; Juhaina Al-Kindi; Najeeb Ur Rehman; Laila Alkalbani; Mohammed Al-Broumi; Nasar Al-Wahaibi; Asem Shalaby; Jamal Al-Sabahi; Ahmed Al-Harrasi; Sulaiman Al-Hashmi
Journal:  J Tradit Complement Med       Date:  2021-10-15

3.  Prevention and treatment of peritoneal adhesions in patients affected by vascular diseases following surgery: a review of the literature.

Authors:  Aldo Rocca; Giovanni Aprea; Giuseppe Surfaro; Maurizio Amato; Antonio Giuliani; Marianna Paccone; Andrea Salzano; Anna Russo; Domenico Tafuri; Bruno Amato
Journal:  Open Med (Wars)       Date:  2016-06-23

4.  The Morphopathogenetic Aspects of Intraabdominal Adhesions in Children under One Year of Age.

Authors:  Anna Junga; Māra Pilmane; Zane Ābola; Olafs Volrāts
Journal:  Medicina (Kaunas)       Date:  2019-08-31       Impact factor: 2.430

5.  Tumor necrosis factor α, protein gene product 9.5, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 presence in congenital intra-abdominal adhesions in children under one year of age.

Authors:  Anna Junga; Māra Pilmane; Zane Ābola; Olafs Volrāts
Journal:  Arch Med Sci       Date:  2021-01-05       Impact factor: 3.318

6.  Breviscapine Pretreatment Inhibits Myocardial Inflammation and Apoptosis in Rats After Coronary Microembolization by Activating the PI3K/Akt/GSK-3β Signaling Pathway.

Authors:  Zhi-Qing Chen; You Zhou; Feng Chen; Jun-Wen Huang; Jing Zheng; Hao-Liang Li; Tao Li; Lang Li
Journal:  Drug Des Devel Ther       Date:  2021-02-25       Impact factor: 4.162

7.  Elucidating the Novel Mechanism of Ligustrazine in Preventing Postoperative Peritoneal Adhesion Formation.

Authors:  Lili Yang; Zhengjun Li; Yao Chen; Feiyan Chen; Haopeng Sun; Min Zhao; Yanqi Chen; Yali Wang; Wenlin Li; Li Zeng; Yaoyao Bian
Journal:  Oxid Med Cell Longev       Date:  2022-03-10       Impact factor: 6.543

8.  Novel cationic lipid nanoparticles as an ophthalmic delivery system for multicomponent drugs: development, characterization, in vitro permeation, in vivo pharmacokinetic, and molecular dynamics studies.

Authors:  Jialu Wang; Fang Zhao; Rui Liu; Jingjing Chen; Qinghua Zhang; Ruijuan Lao; Ze Wang; Xin Jin; Changxiao Liu
Journal:  Int J Nanomedicine       Date:  2017-11-06

Review 9.  Application of Traditional Chinese Medicines in Postoperative Abdominal Adhesion.

Authors:  Fuling Wu; Wenqin Liu; Haixing Feng; Li Long; Lianbing Hou; Chuqi Hou
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-26       Impact factor: 2.629

10.  LincRNA Cox-2 Regulates Lipopolysaccharide-Induced Inflammatory Response of Human Peritoneal Mesothelial Cells via Modulating miR-21/NF-κB Axis.

Authors:  Yaoyao Bian; Lili Yang; Bin Zhang; Wen Li; Sen Wang; Shuling Jiang; Xi Chen; Wenlin Li; Li Zeng
Journal:  Mediators Inflamm       Date:  2019-12-03       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.